Designed to give clinicians a new insight at the first point of care, or through remote monitoring.
Selected, MedTech InnovatorOur AI ECG technology is an investigational device. It has not been approved or cleared by the FDA or any other regulatory authority for diagnostic use.
It's more common than people realize, and often just as easy to overlook.
HFpEF, heart failure with preserved ejection fraction, is especially likely to slip past conventional tests. It routinely goes undiagnosed until it reaches acute care, where mortality risk is already high.
Solution
Designed to assess heart failure risk from a 30-second single-lead ECG wherever a Lead I is captured.
Designed for Lead I from hospital 12-lead ECGs and from wearables.
Research results reported for heart failure overall and for the HFpEF subgroup.
Software-only. Designed to run on existing 12-lead ECG systems (cloud, on-premises, or embedded) and on wearables.
Published research
JACC: Basic to Translational Science (2024) ·
International Journal of Cardiology (2025)





We welcome inquiries from clinicians, researchers, investors, and potential partners.